SCHEMBL5696394

SCHEMBL5696394

CCOC(=O)N1CCCc2cc(C(F)(F)F)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.59
KDM4E B2RXH2 2/20 0.54
LMNA P02545 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HPGD P15428 2/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.44
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
IDO1 P14902 1/20 0.43
KCNH2 Q12809 1/20 0.43
NR3C1 P04150 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
GPBAR1 Q8TDU6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30767099 1.00 NOTUM (0.59) NOTUMKDM4ELMNANPSR1HPGD
SCHEMBL7830913 0.90 CNR2 (0.47) NOTUMKDM4ENPSR1HPGDALDH1A1
SCHEMBL6752845 0.85 NOTUM (0.59) NOTUMKDM4ELMNAHSD17B10MAPT
SCHEMBL8523193 0.85 NOTUM (0.53) NOTUMKDM4ELMNAALDH1A1POLB
SCHEMBL3653813 0.85 NOTUM (0.61) NOTUMKDM4ELMNANPSR1ALDH1A1
SCHEMBL7832103 0.84 NOTUM (0.57) NOTUMKDM4ELMNAHPGDALDH1A1
SCHEMBL30211951 0.84 NOTUM (0.57) NOTUMKDM4ELMNAHPGDALDH1A1
SCHEMBL24011079 0.83 NOTUM (0.84) NOTUMLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL7669258 0.81 NOTUM (0.57) NOTUMKDM4ELMNAHSD17B10MAPT
SCHEMBL7552151 0.81 NOTUM (0.63) NOTUMKDM4ELMNANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076977-A1 METHODS FOR TREATMENT OF DISEASES GALERA LABS LLC (US) 2026-03-19 US disclosed
US-20250017944-A1 METHODS FOR TREATMENT OF DISEASES GALERA LABS, LLC 2025-01-16 US disclosed
CN-117529319-A Orbicifrapib for the treatment of dementia 新阿姆斯特丹制药私人有限公司 2024-02-06 CN disclosed
EP-1670765-A2 CETP INHIBITORS AND METABOLITES THEREOF Pfizer Products Inc. (US) 2006-06-21 EP disclosed
WO-2005033082-A2 CETP INHIBITORS AND METABOLITES THEREOF PFIZER PRODUCTS INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017944-A1 METHODS FOR TREATMENT OF DISEASES SOD1, GLS, GLS2 NOTUM 4155/4885KDM4E 4387/4885LMNA 1540/4885
US-20260076977-A1 METHODS FOR TREATMENT OF DISEASES SOD1, SOD3, CAT NOTUM 3711/4885KDM4E 2325/4885LMNA 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.